Rationale and design of the PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial

BACKGROUND: Recent advances in the treatment algorithms of early breast cancer have markedly improved overall survival. However, anthracycline- and trastuzumab-associated cardiotoxicity may lead to dose-reduction or halt in potentially life-saving adjuvant cancer therapy. Early initiated neurohormon...

Descripción completa

Detalles Bibliográficos
Autores principales: Mecinaj, A, Gulati, G, Heck, SL, Holte, E, Fagerland, MW, Larsen, AI, Blix, E.S, Geisler, J, Wethal, T, Omland, T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474901/
https://www.ncbi.nlm.nih.gov/pubmed/34579775
http://dx.doi.org/10.1186/s40959-021-00115-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474901/
https://www.ncbi.nlm.nih.gov/pubmed/34579775
http://dx.doi.org/10.1186/s40959-021-00115-w

Ejemplares similares